Triple therapy in the management of chronic obstructive pulmonary disease

Triple therapy is superior to both monotherapy and dual therapy for the treatment of advanced chronic obstructive pulmonary disease (COPD), according to a systematic review and meta-analysis.

Triple therapy is superior to both monotherapy and dual therapy for the treatment of advanced chronic obstructive pulmonary disease (COPD), according to a systematic review and meta-analysis. Medical university researchers in China identified 21 randomized clinical trials appropriate for their investigation, which compared the rate of moderate to severe exacerbations associated with each of the three approaches. Triple therapy that included a long acting muscarinic antagonist (LAMA), a long acting beta agonist (LABA), and an inhaled corticosteroid (ICS) significantly reduced the rate of moderate or severe exacerbations compared with LAMA monotherapy, LAMA coupled with LABA, or an ICS/LABA combination. Other favorable outcomes associated with triple therapy included better lung function and improved health-related quality of life. The overall safety profile was favorable overall; however, the incidence of pneumonia much greater with triple therapy than with LAMA/LABA dual therapy.